Delving into ABBV-383, a Novel Bispecific Antibody with Enhanced Tumor Targeting & Optimized T-cell Engagement in Multiple Myeloma

Time: 9:30 am
day: Day One


  • Scientific rationale for high avidity tumor antigen binding coupled with low affinity CD3 T-cell engagement by ABBV-383
  • Translation of unique design attributes of ABBV-383 to the clinic
  • Clinical updates on ABBV-383 in patient with relapsed or refractory multiple myeloma